Sales challenges were also at the forefront of Salesforce’s "State of Sales Report 2024 2 " which surveyed over 5,500 sales professionals and identified that the number one top priority for sales ...

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy ...

In today’s interconnected global economy, maintaining a resilient supply chain is critical. The ability to deliver essential goods, including medications, to the people who need them, when they need ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses results from new data on the role of T cell dysfunction in post-acute infection syndromes.

Despite meeting key pharmacokinetic goals, a potential case of drug-induced liver injury led Pfizer to conclude that danuglipron’s risk-benefit profile did not support further development for chronic ...

Marketing and sales personnel who leverage the expertise and insights of MedAffairs can often have better success.

Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explains how Juvena plans to differentiate JUV-112 from other obesity therapeutics targeting adipose tissue.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research ...

The Verseon CEO discusses how this advanced technology is helping to discover new drug candidates.

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...